TerminatedPhase 1

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

Stopped: Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.

Canada45 participantsStarted 2021-10-18

Plain-language summary

This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with Asthma Exclusion Criteria: \-

What they're measuring

Maximum Percentage Decrease From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Any Time Between 3 and 7 Hours Post-Allergen Challenge

Timeframe: Baseline (pre-allergen challenge on Day 27) and anytime between 3 and 7 hours post-challenge on Day 27

Trial details

NCT IDNCT04987944

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-03-29

Results submitted2024-02-02

View on ClinicalTrials.gov More Asthma trials